MannKind

About:

MannKind focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes.

Top Investors: Deerfield, Deerfield Capital Management

Description:

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product candidate, AFREZZA(R), is in the late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. It maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind.

Total Funding Amount:

$400M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Valencia, California, United States

Founded Date:

2001-01-01

Founders:

Alfred E. Mann

Number of Employees:

501-1000